110 related articles for article (PubMed ID: 7833147)
1. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance.
Sheridan E; Silcocks P; Smith J; Hancock BW; Goyns MH
Eur J Cancer; 1994; 30A(11):1701-4. PubMed ID: 7833147
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
3. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
4. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
[TBL] [Abstract][Full Text] [Related]
5. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
Laframboise S; Chapman W; McLaughlin J; Andrulis IL
Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases.
Ariyoshi K; Kawauchi S; Kaku T; Nakano H; Tsuneyoshi M
Histopathology; 2000 Nov; 37(5):427-36. PubMed ID: 11119124
[TBL] [Abstract][Full Text] [Related]
7. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
[TBL] [Abstract][Full Text] [Related]
8. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
[TBL] [Abstract][Full Text] [Related]
10. Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance.
Suzuki M; Ohwada M; Saga Y; Kohno T; Takei Y; Sato I
Oncology; 2001; 60(2):170-5. PubMed ID: 11244333
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.
Shahin MS; Hughes JH; Sood AK; Buller RE
Cancer; 2000 Nov; 89(9):2006-17. PubMed ID: 11064359
[TBL] [Abstract][Full Text] [Related]
13. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma.
Klemi PJ; Pylkkänen L; Kiilholma P; Kurvinen K; Joensuu H
Cancer; 1995 Oct; 76(7):1201-8. PubMed ID: 8630898
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features.
Renninson J; Baker BW; McGown AT; Murphy D; Norton JD; Fox BW; Crowther D
Br J Cancer; 1994 Mar; 69(3):609-12. PubMed ID: 8123498
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical determination of p53 protein in prostatic cancer and prostatic intraepithelial neoplasms.
Yaman O; Ozdiler E; Orhan D; Sak SD; Baltaci S; Tulunay O; Göğüş O
Urol Int; 1997; 58(4):199-202. PubMed ID: 9253117
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 protein as a predictor of survival in endometrial carcinoma.
Strang P; Nordstöm B; Nilsson S; Bergström R; Tribukait B
Eur J Cancer; 1996 Apr; 32A(4):598-602. PubMed ID: 8695259
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis.
Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Machtens S; Werner M; Jonas U
Cancer; 1996 Nov; 78(9):1958-66. PubMed ID: 8909317
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of p53 tumor suppressor gene protein in canine epithelial colorectal tumors.
Wolf JC; Ginn PE; Homer B; Fox LE; Kurzman ID
Vet Pathol; 1997 Sep; 34(5):394-404. PubMed ID: 9381650
[TBL] [Abstract][Full Text] [Related]
19. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
20. p53 expression in ovarian borderline tumors and stage I carcinomas.
Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]